Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$15.63 - $41.49 $473,604 - $1.26 Million
-30,301 Reduced 52.44%
27,476 $944,000
Q2 2022

Aug 15, 2022

BUY
$11.14 - $23.17 $643,635 - $1.34 Million
57,777 New
57,777 $883,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $291M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Occudo Quantitative Strategies LP Portfolio

Follow Occudo Quantitative Strategies LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

News

Stay updated on Occudo Quantitative Strategies LP with notifications on news.